As a special point, the expression status of RIPK3 in cervical carcinoma cells has also been shown to influence the efficacy of PolyI:C-induced immunotherapy [144], which facilitates the development of a more rational immunotherapy strategy based on the RIPK3 level. Here, RIPK3 is linked to cervical carcinoma.